Immuno 2026 Day 6 Highlights: Dose Optimization and Better Research Decisions
Sep 29, 2026
View online
Immuno 2026 Day 6 Highlights: Dose Optimization and Better Research Decisions
Teva Receives U.S. FDA Approval for Denosumab Biosimilar for Oncology Indications
Julie Gralow: What’s Next for Cancer Prevention in the Asia-Pacific Region?
Pfizer to Present 45 Abstracts at ESMO 2026, With Data in Breast, Genitourinary, Lung Cancers and Melanoma
Soumyajit Roy: External Validation of NADIR in the Phase III ARCHES Trial
EVOLUTE: Enfortumab Vedotin in Older Patients With Advanced Urothelial Carcinoma
10 Must-Read Posts In GI Oncology This Week
Mammo 2026: OncoDaily and Olema Pharmaceuticals Bring Global Breast Cancer Perspectives Together
EACR–Mark Foundation–Pezcoller Foundation Rising Star Award 2027
EACR–Molecular Oncology Editorial Fellowship 2027
ESMO Preceptorship on Supportive Care Needs and Cachexia Management in Cancer Patients 2026
Society for Integrative Oncology (SIO) 2026 Conference
The Voice of Oncology
Unsubscribe
|
Manage subscription
OncoDaily, P53 Inc.
867 Boylston Street, 5th Floor, Suite 1094, Boston, MA 02116
Copyright (C) 2023-2026. OncoDaily, P53 Inc. All rights reserved.
